Type 1 and type 2 T-cell profiles in idiopathic thrombocytopenic purpura

Haematologica

Volumn 90, Issue 7, 2005, Pages 914-923

  Wang, Tingting ^a,b   Zhao, Hui ^a,b   Ren, He ^a,b   Guo, Jianhai ^b   Xu, Maoqiang ^b   Yang, Renchi ^a,b   Han, Zhong Chao ^a,b  

^a PEKING UNION MEDICAL COLLEGE   (China)

^b INSTITUTE OF HEMATOLOGY AND BLOOD DISEASES HOSPITAL   (China)

Author keywords

Idiopathic thrombocytopenic purpura; Tc1; Tc2; Th1; Th2

Indexed keywords

CYTOKINE; IONOMYCIN; T BOX TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR GATA 3; TRANSCRIPTION FACTOR T BET; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CELL CULTURE; CELLULAR IMMUNITY; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IDIOPATHIC THROMBOCYTOPENIC PURPURA; MALE; PERIPHERAL BLOOD MONONUCLEAR CELL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; SPLEEN CELL; T LYMPHOCYTE; TH1 CELL; TH2 CELL; THROMBOCYTE COUNT;

ADOLESCENT; ADULT; CYTOKINES; FEMALE; FLOW CYTOMETRY; GATA3 TRANSCRIPTION FACTOR; HUMANS; LEUKOCYTES, MONONUCLEAR; MALE; MIDDLE AGED; PURPURA, THROMBOCYTOPENIC, IDIOPATHIC; SPLEEN; T-BOX DOMAIN PROTEINS; T-LYMPHOCYTES; TH1 CELLS; TH2 CELLS; TRANSCRIPTION FACTORS;

EID: 22544456923     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (76)

1. Cines DB, Blanchette VS. Immune thrombocytopenic purpura. N Engl J Med 2002;346:995-1008.
2. Yang R and Han ZC. Pathogenesis and management of idiopathic tnrombocytopenic purpura: an update. Int J Hematol 2000;71:18-24
3. Zhou B, Zhao H, Yang RC, Han ZC. Multi-dysfunctional pathophysiology in ITP. Crit Rev Oncol/Hematol. 2005;54:107-16
4. Kuwana M, Kaburaki J, Ikeda Y. Autoreactive T cells to platelet GPIIb-IIIa in immune thrombocytopenic purpura: Role in production of anti-platelet autoantibody. J Clin Invest 1998;102:1393-402.
5. Olsson B, Andersson PO, Jernas M, Jacobsson S, Carlsson B, Carlsson LM, et al. T-cell-mediated cytotoxicity toward platelets in chronic idiopathic thrombocytopenic purpura. Nat Med 2003;9:1123-4.
6. Tsubakio T, Tani P, Curd JG, McMillan R. Complement activation in vitro by antiplatelet antibodies in chronic immune thrombocytopenic purpura. Br J Haematol 1986;63:293-300.
7. Mosmann TR, Cherwinski H, Bond MW, Giedlin MA, Coffman RL. Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins. J Immunol 1986;136:2348-57.
8. Croft M, Carter L, Swain SL, Dutton RW. Generation of polarized antigen-specific CD8 effector populations: reciprocal action of interleukin (IL)-4 and IL-12 in promoting type 2 versus type 1 cytokine profiles. J Exp Med 1994;180:1715-28.
9. Salgame P, Abrams JS, Clayberger C, Goldstein H, Convit J, Modlin RL, et al. Differing lymphokine profiles of functional subsets of human CD4 and CD8 T cell clones. Science 1991;254:279-82.
10. Del Prete GF, De Carli M, Mastromauro C, Biagiotti R, Macchia D, Falagiani P, et al. Purified protein derivative of Mycobacterium tuberculosis and excretory-secretory antigen(s) of Toxocara canis expand in vitro human T cells with stable and opposite (type 1 T helper or type 2 T helper) profile of cytokine production. J Clin Invest 1991;88:346-50.
11. Sad S, Marcotte R, Mosmann TR. Cytokine-induced differentiation of precursor mouse CD8+ T cells into cytotoxic CD8+ T cells secreting Th1 or Th2 cytokines. Immunity 1995;2:271-9.
12. Vukmanovic-Stejic M, Vyas B, Gorak-Stolinska P, Noble A, Kemeny DM. Human Tc1 and Tc2/Tc0 CD8 T-cell clones display distinct cell surface and functional phenotypes. Blood 2000;95:231-40.
13. Lucey DR, Clerici M, Shearer GM. Type 1 and type 2 cytokine dysregulation in human infectious, neoplastic, and inflammatory diseases. Clin Microbiol Rev 1996;9:532-62.
14. Szabo SJ, Kim ST, Costa GL, Zhang X, Fathman CG, Glimcher LH. A novel transcription factor, T-bet, directs Th1 lineage commitment. Cell 2000;100:655-69.
15. Grogan JL, Mohrs M, Harmon B, Lacy DA, Sedat JW, Locksley RM. Early transcription and silencing of cytokine genes underlie polarization of T helper cell subsets. Immunity 2001;14:205-15.
16. Zhang DH, Cohn L, Ray P, Bottomly K, Ray A. Transcription factor GATA-3 is differentially expressed in murine Th1 and Th2 cells and controls Th2-specific expression of the interleukin-5 gene. J Biol Chem 1997;272:21597-603.
17. Ouyang W, Ranganath SH, Weindel K, Bhattacharva D, Murphy TL, Sha WC, et al. Inhibition of Th1 development mediated by GATA-3 through an IL-4-independent mechanism. Immunity 1998;9:745-55.
18. Yu HR, Chang JC, Chen RF, Chuang H, Hong KC, Wang L, et al. Different antigens trigger different Th1/Th2 reactions in neonatal mononuclear cells (MNCs) relating to T-bet/GATA-3 expression. J Leukoc Biol 2003;74:952-8.
19. Chakir H, Wang H, Lefebvre DE, Webb J, Scott FW. T-bet/GATA-3 ratio as a measure of the Th1/Th2 cytokine profile in mixed cell populations: predominant role of GATA-3. J Immunol Methods 2003;278:157-69.
20. Semple JW, Milev Y, Cosgrave D, Mody M, Hornstein A, Blanchette V, et al. Differences in serum cytokine levels in acute and chronic autoimmune thrombocytopenic purpura: relationship to platelet phenotype and antiplatelet T-cell reactivity. Blood 1996;87:4245-54.
21. Andersson J. Cytokines in idiopathic thrombocytopenic purpura (ITP). Acta Paediatr Suppl 1998;424:61-4.
22. Yoshimura C, Nomura S, Nagahama M, Ozaki Y, Kagawa H, Fukuhara S. Plasma-soluble Fas (APO-1, CD95) and soluble Fas ligand in immune thrombocytopenic purpura. Eur J Haematol 2000;64:219-24.
23. Panitsas FP, Theodoropoulou M, Kouraklis A, Karakantza M, Theodorou GL, Zoumbos NC, et al. Adult chronic idiopathic thrombocytopenic purpura (ITP) is the manifestation of a type-1 polarized immune response. Blood 2004;103:2645-7.
24. Ogawara H, Handa H, Morita K, Hayakawa M, Kojima J, Amagai H, et al. High Th1/Th2 ratio in patients with chronic idiopathic thrombocytopenic purpura. Eur J Haematol 2003;71:283-8.
25. Andersson PO, Stockelberg D, Jacobsson S, Wadenvik H. A transforming growth factor-beta1-mediated bystander immune suppression could be associated with remission of chronic idiopathic thrombocytopenic purpura. Ann Hematol 2000;79:507-13.
26. Webber NP, Mascarenhas JO, Crow MK, Bussel J, Schattner EJ. Functional properties of lymphocytes in idiopathic thrombocytopenic purpura. Hum Immunol 2001;62:1346-55.
27. George JN, Woolf SH, Raskob GE, Wasser JS, Aledort LM, Ballem PJ, et al. Idiopathic thrombocytopenic purpura: a practice guideline developed by explicit methods for the American Society of Hematology. Blood 1996;88:3-40.
28. Zhang L, Li H, Zhao H, Ji X, Yang R. Hepatitis C virus-related adult chronic idiopathic thrombocytopenic purpura: experience from a single Chinese center. Eur J Haematol 2003;70:196-7.
29. th Ed. Peking: The People's Health Press, 2003. p. 301-2 (In Chinese).
30. Kuwana M, Okazaki Y, Kaburaki J, Kawakami Y, Ikeda Y. Spleen is a primary site for activation of platelet-reactive T and B cells in patients with immune thrombocytopenic purpura. J Immunol 2002;168:3675-82.
31. Gupta S, Aggarwal S, Rashanravan B, Lee T. Th1- and Th2-like cytokines in CD4+ and CD8+ T cells in autism. J Neuroimmunol 1998;85:106-9.
32. Becher B, Giacomini PS, Pelletier D, McCrea E, Prat A, Antel JP. Interferon-gamma secretion by peripheral blood T-cell subsets in multiple sclerosis: correlation with disease phase and interferon-beta therapy. Ann Neurol 1999;45:247-50.
33. Fowell D, Mason D. Evidence that the T cell repertoire of normal rats contains cells with the potential to cause diabetes. Characterization of the CD4+ T cell subset that inhibits this autoimmune potential. J Exp Med 1993;177:627-36.
34. O'Garra A, Murphy K. T-cell subsets in autoimmunity. Curr Opin Immunol 1993;5:880-6.
35. Powrie F, Coffman RL. Cytokine regulation of T-cell function: potential for therapeutic intervention. Immunol Today 1993;14:270-4.
36. Liblau RS, Singer SM, McDevitt HO. Th1 and Th2 CD4+ T cells in the pathogenesis of organ-specific autoimmune diseases. Immunol Today 1995;16:34-8.
37. Scott B, Liblau R, Degermann S, Marconi LA, Ogata L, Caton AJ, et al. A role for non-MHC genetic polymorphism in susceptibility to spontaneous autoimmunity. Immunity 1994;1:73-83.
38. Karlsson FA, Berne C, Bjork E, Kullin M, Li Z, Ma JY, et al. Beta-cell activity and destruction in type 1 diabetes. Ups J Med Sci 2000;105:85-95.
39. Elson CO, Cong Y, Brandwein S, Weaver CT, McCabe RP, Mahler M, et al. Experimental models to study molecular mechanisms underlying intestinal inflammation. Ann N Y Acad Sci 1998;859:85-95.
40. Prussin C. Cytokine flow cytometry: understanding cytokine biology at the single-cell level. J Clin Immunol 1997;17:195-204.
41. Holmes BJ, MacAry PA, Noble A, Kemeny DM. Antigen-specific CD8+ T cells inhibit IgE responses and interleukin-4 production by CD4+ T cells. Eur J Immunol 1997;27:2657-65.
42. Noble A, Zhao ZS, Cantor H. Suppression of immune responses by CD8 cells. II. Qa-1 on activated B cells stimulates CD8 cell suppression of T helper 2 responses. J Immunol 1998;160:566-71.
43. Williams NS, Engelhard VH. Perforin-dependent cytotoxic activity and lymphokine secretion by CD4+ T cells are regulated by CD8+ T cells. J Immunol 1997;159:2091-9.
44. Srikiatkhachorn A, Braciale TJ. Virus-specific CD8+ T lymphocytes down-regulate T helper cell type 2 cytokine secretion and pulmonary eosinophilia during experimental murine respiratory syncytial virus infection. J Exp Med 1997;186:421-32.
45. Ciubotariu R, Colovai AI, Pennesi G, Liu Z, Smith D, Berlocco P, et al. Specific suppression of human CD4+ Th cell responses to pig MHC antigens by CD8+CD28- regulatory T cells. J Immunol 1998;161:5193-202.
46. Liu Z, Tugulea S, Cortesini R, Suciu-Foca N. Specific suppression of T helper alloreactivity by allo-MHC class I-restricted CD8+CD28- T cells. Int Immunol 1998;10:775-83.
47. Cronin DC 2nd, Stack R, Fitch FW. IL-4-producing CD8+ T cell clones can provide B cell help. J Immunol 1995;154:3118-27.
48. MacAry PA, Holmes BJ, Kemeny DM. Ovalbumin-specific, MHC class I-restricted, alpha beta-positive, Tc1 and Tc0 CD8+ T cell clones mediate the in vivo inhibition of rat IgE. J Immunol 1998;160:580-7.
49. Paganelli R, Scala E, Mezzaroma I, Pinter E, D'Offizi G, Fanales-Belasio E, et al. Immunologic aspects of hyper-immunoglobulinemia E-like syndrome in patients with AIDS. J Allergy Clin Immunol 1995;95:995-1003.
50. Takahashi T, Gray JD, Horwitz DA. Human CD8+ lymphocytes stimulated in the absence of CD4+ cells enhance IgG production by antibody-secreting B cells. Clin Immunol Immunopathol 1991;58:352-65.
51. Hisatsune T, Nishijima K, Kohyama M, Kato H, Kaminogawa S. CD8+ T cells specific to the exogenous antigen. Mode of antigen recognition and possible implication in immunosuppression. J Immunol 1995;154:88-96.
52. McMenamin C, Holt PG. The natural immune response to inhaled soluble protein antigens involves major histocompatibility complex (MHC) class I-restricted CD8+ T cell-mediated but MHC class II-restricted CD4+ T cell-dependent immune deviation resulting in selective suppression of immunoglobulin E production. J Exp Med 1993;178:889-99.
53. Ito N, Nakamura H, Tanaka Y, Ohgi S. Lung carcinoma: analysis of T helper type 1 and 2 cells and T cytotoxic type 1 and 2 cells by intracellular cytokine detection with flow cytometry. Cancer 1999;85:2359-67.
54. Ochi H, Wu XM, Osoegawa M, Horiuchi I, Minohara M, Murai H, et al. Tc1/Tc2 and Th1/Th2 balance in Asian and Western types of multiple sclerosis, HTLV-1-associated myelopathy/tropical spastic paraparesis and hyperIgEaemic myelitis. J Neuroimmunol 2001;119:297-305.
55. Amel-Kashipaz MR, Huggins ML, Lanyon P, Robins A, Todd I, Powell RJ. Quantitative and qualitative analysis of the balance between type 1 and type 2 cytokine-producing CD8 (-) and CD8 (+) T cells in systemic lupus erythematosus. J Autoimmun 2001;17:155-63.
56. Wodarz D, Jansen VA. The role of T cell help for anti-viral CTL responses. J Theor Biol 2001;211:419-32.
57. Abbas AK, Murphy KM, Sher A. Functional diversity of helper T lymphocytes. Nature 1996;383:787-93.
58. Morel PA, Oriss TB. Crossregulation between Th1 and Th2 cells. Crit Rev Immunol 1998;18:275-303.
59. Kojouri K, Vesely SK, Terrell DR, George JN. Splenectomy for adult patients with idiopathic thrombocytopenic purpura: a systematic review to assess long-term platelet count responses, prediction or response, and surgical complications. Blood 2004;104:2623-34.
60. Sandler SG. The spleen and splenectomy in immune (idiopathic) thrombocytopenic purpura. Semin Hematol 2000;37:10-2.
61. Szabo SJ, Sullivan BM, Stemmann C, Satoskar AR, Sleckman BP, Glimcher LH. Distinct effects of T-bet in TH1 lineage commitment and IFN-gamma production in CD4 and CD8 T cells. Science 2002;295:338-42.
62. Ferber IA, Lee HJ, Zonin F, Heath V, Mui A, Arai N, et al. GATA-3 significantly downregulates IFN-gamma production from developing Th1 cells in addition to inducing IL-4 and IL-5 levels. Clin Immunol 1999;91:134-44.
63. Ranganath S, Ouyang W, Bhattarcharya D, Sha WC, Grupe A, Peltz G, et al. GATA-3-dependent enhancer activity in IL-4 gene regulation. J Immunol 1998;161:3822-6.
64. Li-Weber M, Salgame P, Hu C, Davydov IV, Laur O, Klevenz S, et al. Th2-specific protein/DNA interactions at the proximal nuclear factor-AT site contribute to the functional activity of the human IL-4 promoter. J Immunol 1998;161:1380-9.
65. Akashi K, Traver D, Miyamoto T, Weissman IL. A clonogenic common myeloid progenitor that gives rise to all myeloid lineages. Nature 2000;404:193-7.
66. Hattori N, Kawamoto H, Fujimoto S, Kuno K, Katsura Y. Involvement of transcription factors TCF-1 and GATA-3 in the initiation of the earliest step of T cell development in the thymus. J Exp Med 1996;184:1137-47.
67. Nawijn MC, Ferreira R, Dingjan GM, Kahre O, Drabek D, Karis A, et al. Enforced expression of GATA-3 during T cell development inhibits maturation of CD8 single-positive cells and induces thymic lymphoma in transgenic mice. J Immunol 2001;167:715-23.
68. Hernandez-Hoyos G, Anderson MK, Wang C, Rothenberg EV, Alberola-Ila J. GATA-3 expression is controlled by TCR signals and regulates CD4/CD8 differentiation. Immunity 2003;19:83-94.
69. Mylvaganam R, Ahn YS, Harrington WJ, Kim CI. Immune modulation by danazol in autoimmune thrombocytopenia. Clin Immunol Immunopathol 1987;42:281-7.
70. Scott CS, Wheeler R, Ford P, Bynoe AG, Roberts BE. T lymphocyte subpopulations in idiopathic thrombocytopenic purpura (ITP). Scand J Haematol 1983;30:401-6.
71. Mylvaganam R, Ahn YS, Harrington WJ, Kim CI, Gratzner HG. Differences in T cell subsets between men and women with idiopathic thrombocytopenic purpura. Blood 1985;66:967-72.
72. de Jong R, Altare F, Haagen IA, Elfe rink DG, Boer T, van Breda Vriesman PJ, et al. Severe mycobacterial and Salmonella infections in interleukin-12 receptor-deficient patients. Science 1998;280:1435-8.
73. Ottenhoff TH, de Boer T, Verhagen CE, Verreck FA, van Dissel JT. Human deficiencies in type 1 cytokine receptors reveal the essential role of type 1 cytokines in immunity to intracellular bacteria. Microbes Infect 2000;2:1559-66.
74. Singh VK, Mehrotra S, Agarwal SS. The paradigm of Th1 and Th2 cytokines: its relevance to autoimmunity and allergy. Immunol Res 1999;20:147-61.
75. Doyle HA, Mamula MJ. Post-translational protein modifications in antigen recognition and autoimmunity. Trends Immunol 2001;22:443-9.
76. Coutinho A, Haas W. In vivo models of dominant T-cell tolerance: where do we stand today? Trends Immunol 2001;22:350-1.